A61P 35 - Antineoplastic agents

Patents for A61P 35 - Antineoplastic agents (221,099)
11/2002
11/26/2002	US6486305 Method of modulating the efficiency of translation termination and degradation of aberrant mrna involving a surveillance complex comprising human upf1p, eucaryotic release factor 1 and eucaryotic release factor 3
11/26/2002	US6486210 Such as enantiomorphs of 4-fluorostyryl-2,3,4,5,6-pentafluorobenzylsulfone; antiproliferative/anticancer agents
11/26/2002	US6486199 Spiro and dispiro 1,2,4-trioxolane antimalarials
11/26/2002	US6486187 N-[4-(heteroarylmethyl)phenyl]-heteroarylamines
11/26/2002	US6486186 Thiazole compounds as cyclic AMP-specific phosphodiesterase inhibitors and method of using the same
11/26/2002	US6486185 3-heteroarylidene-2-indolinone protein kinase inhibitors
11/26/2002	US6486179 Use of protein kinase C inhibitors to enhance the clinical efficacy of oncolytic agents and radiation therapy
11/26/2002	US6486177 Methods for treatment of cognitive and menopausal disorders with D-threo methylphenidate
11/26/2002	US6486167 Heterocyclic cytotoxic agents
11/26/2002	US6486158 [4,5]-fused-3,6-disubstituted-pyridazines with sulfur-containing substituents in position three for the treatment of neoplasia
11/26/2002	US6486156 Chemical compounds
11/26/2002	US6486144 Method of treatment of liver tumors and pharmaceutical compositions for use therein
11/26/2002	US6486142 Phosphonic acid derivatives as inhibitors of protein tyrosine phosphatase 1B (PTP-1B)
11/26/2002	US6486141 Phosphonic acid biaryl derivatives as inhibitors of protein tyrosine phosphatase 1B (PTP-1B)
11/26/2002	US6486132 Immunomodulator, immunomodulator food and immunomodulator feed
11/26/2002	US6486122 Methods of increasing body weight in a subject by administering TGF-α
11/26/2002	US6485960 Polycystic kidney disease 1 gene and uses thereof
11/26/2002	US6485755 Methods of using electron active compounds for managing cancer
11/26/2002	US6485724 Immortalized human keratinocyte cell line
11/26/2002	US6485704 Azo compound for type I pototherapy
11/26/2002	CA2258285C Substituted indazole derivatives and their use as phosphodiesterase (pde) type iv and tumor necrosis factor (tnf) inhibitors
11/26/2002	CA2148103C Process for preparing taxane derivatives
11/26/2002	CA2111573C Cadherin materials and methods
11/26/2002	CA2095214C Agents for the treatment of diseases caused by parasitic protozoa and neoplastic diseases
11/26/2002	CA2093203C Pyrimidine derivatives and processes for the preparation thereof
11/26/2002	CA2087164C Target specific antibody-superantigen conjugates and their preparation
11/26/2002	CA2078555C Novel vitamin d analogues
11/26/2002	CA2076465C Cell binding agent conjugates of analogues and derivatives of cc-1065
11/26/2002	CA2067184C New linker for bioactive agents
11/26/2002	CA2060330C Compositions and method for soft tissue tumors
11/26/2002	CA2051289C Viral mediated destruction of neoplastic cells
11/23/2002	CA2382443A1 Use of anti-ctla-4 antibodies
11/21/2002	WO2002093177A2 Assays for identifying modulators of rhomboid polypeptides
11/21/2002	WO2002092854A2 Genes expressed in breast cancer as prognostic and therapeutic targets
11/21/2002	WO2002092842A2 Nucleic acids and corresponsing proteins entitled 101p3a11 or phor-1 useful in treatment and detection of cancer
11/21/2002	WO2002092841A2 Nucleic acid molecules encoding a transmembrane serine protease 10, the encoded polypeptides and methods based thereon
11/21/2002	WO2002092840A2 Agents that regulate apoptosis
11/21/2002	WO2002092832A2 Human and non-human primate homologues of nkd protein, nucleic acid sequences encoding, and uses thereof
11/21/2002	WO2002092827A2 Corona-virus-like particles comprising functionally deleted genomes
11/21/2002	WO2002092826A2 Composition and method for treating cancer using herpes virus
11/21/2002	WO2002092816A1 Replication vector showing cell-specific expression
11/21/2002	WO2002092808A1 Random gene unidirectional antisense library
11/21/2002	WO2002092807A1 Unigene unidirectional antisense library
11/21/2002	WO2002092796A1 Papilloma pseud-virus and it's preparation
11/21/2002	WO2002092782A2 Diagnosis and treatment of malignant neoplasms
11/21/2002	WO2002092781A2 Peptide compounds for counteracting reactive oxygen species and free radicals
11/21/2002	WO2002092772A2 Antisense modulation of ptp1b expression
11/21/2002	WO2002092771A2 Specific binding proteins and uses thereof
11/21/2002	WO2002092759A2 Molecules for disease detection and treatment
11/21/2002	WO2002092667A1 Biodegradable polyphosphates for controlled release of bioactive substances
11/21/2002	WO2002092635A2 Immunologic compositions and methods for studying and treating cancers expressing frizzled antigens
11/21/2002	WO2002092629A1 Polynucleotides and polypeptides linked to cancer and/or tumorigenesis
11/21/2002	WO2002092627A2 Use of casb 7439 for treatment and diagnosis of lung cancer
11/21/2002	WO2002092623A1 INHIBITORS OF RECEPTOR ACTIVATOR OF NF-κB AND USES THEREOF
11/21/2002	WO2002092620A2 Peptides and related molecules that bind to tall-1
11/21/2002	WO2002092617A1 Combined approach to treatment of cancer using a c-myc antisense oligomer
11/21/2002	WO2002092616A1 Antisense permeation enhancers
11/21/2002	WO2002092603A1 Oxazolo-and furopyrimidines and their use in medicaments against tumors
11/21/2002	WO2002092600A1 Retinol derivatives potentiation of active substances by micellar preparation
11/21/2002	WO2002092599A1 4-amino-5-phenyl-7-cyclobutyl-pyrrolo (2,3-d) pyrimidine derivatives
11/21/2002	WO2002092594A1 Substituted 4h-chromenes and analogs as activators of caspases and inducers of apoptosis and the use thereof
11/21/2002	WO2002092593A1 4-(4-pyridazinyl)pyrazole derivatives
11/21/2002	WO2002092589A2 Novel decalactones from associated fungi of marine sponges and their synthetic derivatives as medicaments
11/21/2002	WO2002092588A2 Aromatic sulfone hydroxamates and their use as protease inhibitors
11/21/2002	WO2002092579A1 4-anilinoquinazoline derivatives
11/21/2002	WO2002092573A2 Heterocyclic substituted pyrazoles as inhibitors of src and other protein kinases
11/21/2002	WO2002092571A1 Novel 4-anilinoquinoline-3-carboxamides
11/21/2002	WO2002092565A2 3-aminoalkyl-2-aryl-indole derivatives and their use as gnrh antagonists
11/21/2002	WO2002092563A2 Protease inhibitors
11/21/2002	WO2002092558A1 Polythiourea lipid derivatives
11/21/2002	WO2002092553A1 Hydroxamic acids and acyl hydroxamines as naaladase inhibitors
11/21/2002	WO2002092136A2 Immunoconjugates made of egg-yolk antibodies (igy), production and use thereof in diagnoses and therapy
11/21/2002	WO2002092133A1 Angiogenesis inhibitors
11/21/2002	WO2002092129A2 Pharmaceutical combination comprising an anti-androgen and an oestrogen receptor beta agonist
11/21/2002	WO2002092127A1 Anti-cd26 monoclonal antibodies as therapy for diseases associated with cells expressing cd26
11/21/2002	WO2002092126A1 Binding member which binds to both lewis-y and lewis-b haptens, and its use for treating cancer
11/21/2002	WO2002092111A1 Use of extracts and preparations from iris plants and tectorigenin as medicaments
11/21/2002	WO2002092103A1 Chemoprotection using amifostine and related compounds
11/21/2002	WO2002092100A1 17-(c(ch3) (ch2) o-3c (r4, r5) n (r6, r7))-substituted 19-nor-pregna-1, 3, 5(10)-triene derivatives and their medical use
11/21/2002	WO2002092096A1 Antitumor agents
11/21/2002	WO2002092091A1 Combination comprising n-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2pyrimidine-amine and a chemotherapeutic agent
11/21/2002	WO2002092089A1 Tartrate salts of 5,8,14-triazatetracyclo {10.3.1.0?2,11.04,9¿}-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof
11/21/2002	WO2002092087A1 2,5-disubstituted pyridine, pyrimidine, pyridazine and 1, 2, 4-triazine derivatives for use as p38 inhibitors
11/21/2002	WO2002092079A1 Utilization of selective indirubin derivatives as vegf-r inhibitors
11/21/2002	WO2002092075A2 Therapeutic delivery of carbon monoxide
11/21/2002	WO2002092069A1 Permeation enhancers
11/21/2002	WO2002092066A1 Antitumor preparation devoid of side effect
11/21/2002	WO2002092055A1 Oxidized collagen formulations for use with non-compatible pharmaceutical agents
11/21/2002	WO2002092016A2 Therapeutic use of rank antagonists
11/21/2002	WO2002092012A2 Compositions and methods for treating tumors bearing hmfg and cea antigens
11/21/2002	WO2002091997A2 Oncolytic virus therapy
11/21/2002	WO2002091996A2 Methods for treating cancer
11/21/2002	WO2002091993A2 Estrogen receptor modulators
11/21/2002	WO2002091991A2 Substantially homogeneous bio-affecting material having a pre-determined ratio of bioaffecting component to cell targeting component, the method for making such a material and the method of its use
11/21/2002	WO2002091989A2 Antiviral therapies using polyamine or polyamine analog-amino acid conjugates
11/21/2002	WO2002081728A3 Quinoline inhibitors of hyak1 and hyak3 kinases
11/21/2002	WO2002078716A3 Methylated promoters for intraductal treatment of breast cancer
11/21/2002	WO2002076381A3 Proanthocyanidins for the treatment of amyloid and alpha-synuclein diseases
11/21/2002	WO2002074981A3 Assays, methods and means relating to hypoxia inducible factor (hif) hydroxylase
11/21/2002	WO2002074309A3 Use of tryptophan derivatives for the specific cytostatic treatment of serotonin-producing tumors

1 ... 1636 1637 1638 1639 1640 1641 1642 1643 1644 1645 1646 1647 1648 1649 1650 1651 1652 1653 1654 1655 1656 ... 2211